source
- Roivant's autoimmune drug brepocitinib succeeds in two pivotal trials, paving way for 2027 filingRoivant Sciences said its autoimmune drug brepocitinib met primary goals in two pivotal studies. The trials, which evaluated the drug in separate autoimmune indications, showed statistically signi…
- Pfizer halts Phase 2 trial of PF-06835375 in primary immune thrombocytopeniaPfizer announced that it is stopping its Phase 2 study of the experimental program PF-06835375, which was being evaluated in patients with primary immune thrombocytopenia, a rare autoimmune blood d…